RERobin Erickson

Robin Erickson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robin Erickson has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early-Start Versus Late-Start Icodextrin for Children Receiving Chronic Peritoneal Dialysis

    by Priyanka Khandelwal, Dagmara Borzych-Dużałka, Jonas Hofstetter, Bruno Ranchin, Karel Vondrak, Yo Han Ahn, Hui Kim Yap, Hazem Subhi Awad, Nakysa Hooman, Robin Erickson, et al.

    Key Points: Early icodextrin use preserved residual kidney function and improved BP versus glucose dialysate in pediatric peritoneal dialysis patients. Starting icodextrin within 1 year of commencing peritoneal dialysis reduced the risk of technique failure or death nearly five-fold versus later start. Children younger than 5 years on icodextrin had similar ultrafiltration and BP control with superior kidney function preservation versus older children. Background: Experience with icodextrin use in children on long-term peritoneal dialysis (PD) is limited. We describe international icodextrin prescription practices and their effect on clinical outcomes: ultrafiltration, BP control, residual kidney function (RKF), technique and patient survival. Methods: We included patients younger than 21 years enrolled in the International Pediatric Peritoneal Dialysis Network between 2007 and 2024, on automated PD with a daytime dwell. Outcome analysis was restricted to patients with 6 months or greater follow-up. We used propensity score matching to balance baseline differences between icodextrin and glucose groups. Long-term outcomes and survival were analyzed by longitudinal linear mixed-effects models and Cox proportional hazards models, respectively, adjusting for key covariates. Sensitivity analyses addressed the effect of missing data. Results: Icodextrin was prescribed in 724 of 3573 (20.3%) patients, varying widely across world regions. Only “early-start” icodextrin (within 1 year of PD start) was associated with a significant decline in diastolic BP standard deviation score ( β =−1.31, P < 0.001) and a slower decline in RKF ( β =0.11, P = 0.002) compared with glucose use alone. “Late-starters” (starting icodextrin after ≥1 year on PD) compared with “early-starters” had more uncontrolled hypertension (38% versus 20%; P < 0.001), a higher antihypertensive agent requirement (68% versus 55%; P = 0.03) and an higher dialytic glucose exposure from baseline (5.4 versus 4.8 gm/kg per day; P = 0.05). Icodextrin use, both early and late, was independently associated with a positive linear increase in ultrafiltration sustained during follow-up compared with glucose use ( β =0.27 and β =0.33, respectively; both P < 0.01). Peritonitis rates and dialysate leaks were similar between icodextrin and glucose groups. “Late-starters” had significantly increased risk of technique failure/death compared with “early-starters” (hazard ratio, 5.16; 95% confidence intervals, 1.57 to 17.0; P = 0.007). Conclusion: Icodextrin use improves ultrafiltration, but only early compared with delayed initiation conferred a five-fold higher likelihood of technique survival, better BP control, and preservation of RKF. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.www.asn-online.org/media/podcast/CJASN/2025_12_18_CJASNDecember.20.12.mp3


  • Open Access

    Global prevalence of chronic kidney disease and associated risk factors in children and adolescents: protocol for a systematic review and meta-analysis

    by Erin Hedin, Somkanya Tungsanga, Feng Ye, Janice Y Kung, Ikechi Okpechi, Allison B Dart, Stephanie Thompson, Catherine Morgan, Robin Erickson, Swasti Chaturvedi, et al.

    Introduction: While chronic kidney disease (CKD) is well characterised in adults, less is known about the prevalence of CKD in children and adolescents, where it is rare and associated with unique characteristics and implications for long-term health outcomes. This study protocol outlines a systematic review to assess the global prevalence of CKD in children and adolescents along with causes and associated risk factors. This is warranted to better characterise prevalence and to identify at-risk groups that would benefit from screening efforts. We will explore the risk and burden of CKD and its variations by sociodemographic characteristics (age group, race, sex/gender) and geographical regions (country, International Society of Nephrology region and income groups based on World Bank country classifications). Methods and analysis: We will conduct a systematic review of studies reporting on the prevalence of CKD in children and adolescents following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 (PRISMA-P-2015) and the PRISMA 2020 methodological guidelines (PRISMA 2020). Searches will be undertaken in the following databases with the date range from 2000 to date: Ovid MEDLINE, Ovid Embase, CINAHL, Cochrane Library, ProQuest Dissertations & Theses Citation Index (via Clarivate), Web of Science Core Collection, Google Scholar and grey literature sites (registries, government reports) to identify studies that report on the prevalence of CKD in children and adolescents from ages 0 to 18. The primary outcome will be the global prevalence of CKD in children and adolescents. Secondary outcomes will include the causes of and risk factors for CKD, and examining differences and temporal trends in CKD prevalence across countries, geographical regions, income levels and sociodemographic characteristics. Ethics and dissemination: No direct involvement with patient data will be used in this systematic review, as data will be obtained from previously published reports. Ethical approval is therefore not required. Our findings will be published in an open-access peer-reviewed journal and presented at scientific conferences. PROSPERO registration number: CRD42024547467.


  • Open Access

    Disparities in kidney care in vulnerable populations: A multinational study from the ISN-GKHA

    by Robin L. Erickson, Nivedita Kamath, Arpana Iyengar, Adebowale Ademola, Christopher Esezobor, Rowena Lalji, Erin Hedin, Silvia Arruebo, Fergus J. Caskey, Sandrine Damster, et al.

    Vulnerable populations, such as the elderly, children, displaced people, and refugees, often encounter challenges in accessing healthcare. In this study, we used data from the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to describe kidney care access and delivery to vulnerable populations across countries and regions. Using data from an international survey of clinicians, policymakers, and patient advocates, we assessed the funding and coverage of vulnerable populations on all aspects of kidney replacement therapies (KRT). Overall, 167 countries or jurisdictions participated in the survey, representing 97.4% of the world’s population. Children had less access than adults to KRT: hemodialysis (HD) in 74% of countries, peritoneal dialysis (PD) in 53% of countries, and kidney transplantation (KT) in 80% of countries. Available nephrologist workforce for pediatric kidney care was much lower than for adults (0.69 per million population [pmp] vs 10.08 pmp). Refugees or displaced people with kidney failure did not have access to HD, PD, or KT in 21%, 33%, and 37% of the participating countries, respectively. Low-income countries (LICs) were less likely to provide KRT access to refugees compared to high-income countries (HICs): HD: 13% vs 22%; PD: 19% vs 61%; KT: 30% vs 44%. Testing for kidney disease was routinely offered to elderly people in only 61% of countries: LICs (45%), lower-middle-income countries (56%), upper-middle-income countries (54%), and HICs (75%). Equitable access to kidney care for vulnerable people, particularly for children and displaced people, remains an area of unmet need. Strategies are needed to address this issue.


  • Open Access

    A variant in acis-regulatory element enhances claudin-14 expression and is associated with pediatric-onset hypercalciuria and kidney stones

    by Megan E. Ure, Emma Heydari, Wanling Pan, Ajay Ramesh, Sabah Rehman, Catherine Morgan, Maury Pinsk, Robin Erickson, Johannes M. Herrmann, Henrik Dimke, et al.

    The greatest risk factor for kidney stones is hypercalciuria, the etiology of which is largely unknown. A recent genome-wide association study (GWAS) linked hypercalciuria and kidney stones to a claudin-14 (CLDN14) risk haplotype. However, the underlying molecular mechanism was not delineated. Recently, renal CLDN14 expression was found to increase in response to increased plasma calcium, thereby inducing calciuria. We hypothesized therefore that some children with hypercalciuria and kidney stones harbor a CLDN14 variant that inappropriately increases gene expression. To test this hypothesis, we sequenced the CLDN14 risk haplotype in a cohort of children with idiopathic hypercalciuria and kidney stones. An intronic single nucleotide polymorphism (SNP) was more frequent in affected children. Dual luciferase and cell based assays demonstrated increased reporter or CLDN14 expression when this polymorphism was introduced. In silico studies predicted the SNP introduced a novel insulinoma-associated 1 (INSM1) transcription factor binding site. Consistent with this, repeating the dual luciferase assay in the presence of INSM1, further increased reporter expression. Our data suggest that children with the INSM1 binding site within the CLDN14 risk haplotype have a higher likelihood of hypercalciruia and kidney stones. Enhanced CLDN14 expression may play a role in the pathophysiology of their hypercalciuria. This article is protected by copyright. All rights reserved